Provided by Tiger Trade Technology Pte. Ltd.

Tiziana Life Sciences PLC

1.11
+0.156316.39%
Post-market: 1.10-0.0100-0.90%18:54 EDT
Volume:1.52M
Turnover:1.64M
Market Cap:140.97M
PE:-7.12
High:1.14
Open:0.9950
Low:0.9667
Close:0.9537
52wk High:2.33
52wk Low:0.7615
Shares:127.00M
Float Shares:64.88M
Volume Ratio:2.13
T/O Rate:2.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1558
EPS(LYR):-0.1558
ROE:-924.32%
ROA:-115.96%
PB:2710.96
PE(LYR):-7.12

Loading ...

Tiziana Life Sciences - Submits Request to FDA for Orphan Drug Designation for Intranasal Foralumab for Msa

Reuters
·
Yesterday

Tiziana Life announces first 3 participants received first dose in ALS BANYAN

TIPRANKS
·
Sep 28

Tiziana Life Sciences Doses First Patients in Phase 2a Intranasal Foralumab ALS Trial

Reuters
·
Sep 28

Tiziana Life Sciences Announces First Participants Dosed in ALS Banyan Clinical Trial of Intranasal Foralumab

THOMSON REUTERS
·
Sep 28

Tiziana Life Sciences Price Target Maintained with a $7.00/Share by BTIG

Dow Jones
·
Sep 22

Tiziana Life Sciences Completes Phase 2a Inform-MS Last Patient Visit for Intranasal Foralumab in Na-SPMS

Reuters
·
Sep 21

Tiziana Announces Last Patient Completes Last Visit in Phase 2a Inform-MS Trial of Intranasal Foralumab

THOMSON REUTERS
·
Sep 21

Tiziana Life Sciences signs MOU with KAIMRC in Saudi Arabia

TIPRANKS
·
Sep 17

Tiziana Life Sciences Signs MOU at Riyadh Global Medical Biotechnology Summit

Reuters
·
Sep 17

Tiziana Life Sciences Announces Signing of Mou with King Abdullah International Medical Research Center

THOMSON REUTERS
·
Sep 17

Tiziana Life Sciences - Mou Covers Clinical Trial of Foralumab and Anti-Cd20 in Rrms Patients

THOMSON REUTERS
·
Sep 17

Tiziana Life Sciences Initiated at Buy by BTIG

Dow Jones
·
Sep 03

Tiziana Life Sciences Ltd : Btig Initiates Coverage with Buy Rating; Price Target $7

THOMSON REUTERS
·
Sep 03

Tiziana Life Sciences Launches Phase 2a Banyan Trial of Intranasal Foralumab in ALS

Reuters
·
Aug 24

Tiziana Life Sciences Announces Poster Presentation on Phase 2a Banyan Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

THOMSON REUTERS
·
Aug 24

Tiziana Life Sciences CEO Elrifi Buys USD 321,423 in Shares

Reuters
·
Aug 06

Press Release: Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Dow Jones
·
Aug 06

Tiziana CEO Ivor Elrifi Acquires 667,000 Common Shares for $667,000

Reuters
·
Aug 06

Tiziana Life Sciences CEO Ivor Elrifi Lifts Stake to 4,472,261 Shares After Buying 667,000 at $1 Apiece

Reuters
·
Aug 04

Press Release: Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Dow Jones
·
Aug 04